Drug Profile
BMS 986249
Alternative Names: Anti-CTLA-4 Probody - Bristol-Myers Squibb; Anti-CTLA-4 Probody IO - Bristol-Myers Squibb; BMS-986249; CTLA-4-directed probody therapeuticLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator CytomX Therapeutics
- Developer Bristol-Myers Squibb
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Malignant melanoma; Solid tumours
Most Recent Events
- 09 Sep 2022 Efficacy, pharmacodynamics, pharmacokinetics and adverse events data from a phase I/IIa trial in Solid tumours presented at 47th European Society for Medical Oncology Congress
- 13 Jun 2022 Phase-II clinical trials in Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in Germany, Finland, Romania, Canada, Poland, Chile, Australia, Spain, Italy, Argentina, USA (Parenteral) (CytomX Therapeutics pipeline, June 2022)
- 13 Jun 2022 Phase-II clinical trials in Malignant melanoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Recurrent) in USA, Australia, Argentina, Chile, Canada, Germany, Italy, Spain, Finland, Poland, Romania (Parenteral) (CytomX Therapeutics pipeline, June 2022)